Home » Newsletters » BioWorld

BioWorld

Feb. 2, 2000

View Archived Issues

PDL To Raise $100M In Private Offering Of Convertible Notes

Other News To Note

Deltagen Raises $22.5M For Functional Genomics Programs

Appointments and Advancements

Human Genome Sciences Finds Antagonist To Allergy-Stoking Chemokine Receptor; Trials Soon

Biogen Plans To Seek Broader Label Following Avonex Study

United Therapeutics Initiates Another Phase III Of Beraprost

Celera Seeks More Than $300M With Follow-On Stock Offering

Genomics Surge Continues With Sequenom's $137M IPO

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 17, 2024.
Second insulin receptor offers new therapeutic avenues
BioWorld Science
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...
Mechanism underlying so-called idiopathic autism inception unveiled
BioWorld Science
Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.